Ajay Kshatriya

Mr. Ajay Kshatriya’s career mission is to build science-based companies. Currently, Ajay is the Chief Executive Officer of Aizen Therapeutics, pioneering AI to advance a new class of peptide drugs to treat a variety of unmet diseases. He also serves as a Operating Partner at Wilson Hill Ventures, an early stage venture capital firm, where he invests in science-based startups emerging from the California Institute of Technology. Previously, Ajay co-founded and served as Chief Executive Officer of Biota, a pioneer in environmental genomics, that was backed by illumina, achieved 8-digit revenue, and acquired by the industrial biotech leader, Novozymes. Prior to founding Biota, Ajay was an associate VC in a $100M seed fund spun out from Mohr Davidow Ventures, XSeed Capital, that formed companies from science innovations emerging from Stanford and Berkeley. Ajay began his career at the world-leading biotechnology pioneer Genentech, where he held various positions in product operations, including two product core teams in early stage oncology. Ajay holds a B.S. in chemical engineering from UC Berkeley, an M.S. in engineering from Stanford University, and an MBA from Berkeley-Haas School of Business.